Geron Co. (NASDAQ:GERN - Get Free Report) fell 2% during trading on Friday . The stock traded as low as $1.64 and last traded at $1.64. 2,307,806 shares traded hands during trading, a decline of 80% from the average session volume of 11,339,304 shares. The stock had previously closed at $1.67.
Analysts Set New Price Targets
Several research firms have recently commented on GERN. Barclays restated an "overweight" rating and set a $4.00 price objective (down previously from $9.00) on shares of Geron in a report on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and set a $5.00 price objective on shares of Geron in a report on Wednesday, March 12th. B. Riley downgraded Geron from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $3.50 to $2.00 in a report on Thursday, February 27th. Stifel Nicolaus decreased their price objective on Geron from $8.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Finally, Scotiabank cut their target price on Geron from $6.00 to $4.00 and set a "sector outperform" rating on the stock in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Geron currently has a consensus rating of "Moderate Buy" and an average target price of $5.75.
Read Our Latest Stock Analysis on GERN
Geron Stock Performance
The stock has a market capitalization of $1.11 billion, a P/E ratio of -5.45 and a beta of 0.53. The company has a 50 day simple moving average of $2.55 and a 200-day simple moving average of $3.54. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74.
Geron (NASDAQ:GERN - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). The firm had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. On average, equities analysts forecast that Geron Co. will post -0.25 EPS for the current year.
Institutional Trading of Geron
Several hedge funds have recently made changes to their positions in the company. Alternative Investment Advisors LLC. raised its stake in shares of Geron by 13.3% during the 3rd quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company's stock valued at $101,000 after purchasing an additional 2,612 shares during the period. Rovin Capital UT ADV increased its stake in Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 3,660 shares during the last quarter. Xponance Inc. increased its stake in Geron by 12.9% in the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company's stock worth $150,000 after acquiring an additional 4,829 shares during the last quarter. KBC Group NV increased its stake in Geron by 45.1% in the 4th quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 7,592 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in Geron in the 4th quarter worth about $28,000. 73.71% of the stock is currently owned by institutional investors.
About Geron
(
Get Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Recommended Stories
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
